BR112015028869A2 - nanocápsula de emulsão dupla conjugada de anticorpo e métodos de preparação da mesma - Google Patents
nanocápsula de emulsão dupla conjugada de anticorpo e métodos de preparação da mesmaInfo
- Publication number
- BR112015028869A2 BR112015028869A2 BR112015028869A BR112015028869A BR112015028869A2 BR 112015028869 A2 BR112015028869 A2 BR 112015028869A2 BR 112015028869 A BR112015028869 A BR 112015028869A BR 112015028869 A BR112015028869 A BR 112015028869A BR 112015028869 A2 BR112015028869 A2 BR 112015028869A2
- Authority
- BR
- Brazil
- Prior art keywords
- double emulsion
- antibody conjugated
- conjugated double
- preparation methods
- emulsion nanocapsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
1/1 resumo nanocápsula de emulsão dupla conjugada de anticorpo e métodos de preparação da mesma uma nanocápsula de emulsão dupla conjugada de anticorpo é fornecida. um grupo de ligação é introduzido na superfície de uma nanocápsula de emulsão dupla, que é composta por um revestimento oleoso que envolve um núcleo aquoso, para ligar a nanocápsula de emulsão dupla com um anticorpo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW102119370 | 2013-05-31 | ||
TW102140127A TWI482782B (zh) | 2013-05-31 | 2013-11-05 | 架接抗體之雙乳化核殼奈米結構 |
US14/260,726 US9603798B2 (en) | 2013-05-31 | 2014-04-24 | Antibody-conjugated double-emulsion nanocapsule and preparation methods thereof |
PCT/US2014/040107 WO2014194150A1 (en) | 2013-05-31 | 2014-05-30 | Antibody-conjugated double-emulsion nanocapsule and preparation methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015028869A2 true BR112015028869A2 (pt) | 2017-07-25 |
Family
ID=51985365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015028869A BR112015028869A2 (pt) | 2013-05-31 | 2014-05-30 | nanocápsula de emulsão dupla conjugada de anticorpo e métodos de preparação da mesma |
Country Status (11)
Country | Link |
---|---|
US (1) | US9603798B2 (pt) |
EP (1) | EP3003280A4 (pt) |
JP (1) | JP6335281B2 (pt) |
KR (1) | KR101767906B1 (pt) |
CN (1) | CN104208717B (pt) |
AU (1) | AU2014274028B2 (pt) |
BR (1) | BR112015028869A2 (pt) |
CA (1) | CA2910076C (pt) |
RU (1) | RU2015148841A (pt) |
TW (1) | TWI482782B (pt) |
WO (1) | WO2014194150A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105832702B (zh) * | 2015-01-13 | 2019-02-22 | 胡尚秀 | 用于药物传递的蛋白质纳米磁性壳核胶囊及其应用 |
WO2017165506A1 (en) * | 2016-03-23 | 2017-09-28 | Academia Sinica | Thin-shell polymeric nanoparticles and uses thereof |
CN108685872B (zh) * | 2017-04-12 | 2020-11-20 | 刘东飞 | 一种序列沉淀络合凝聚法制备超高载药纳米粒子的方法 |
TWI664983B (zh) * | 2017-05-01 | 2019-07-11 | 中國醫藥大學 | 免疫磁性組成物、其製備方法、其用途以及治療癌症之套組 |
US10736964B2 (en) * | 2017-05-01 | 2020-08-11 | China Medical University | Immunomagnetic nanocapsule and kit for treating cancer |
KR102176034B1 (ko) * | 2018-06-22 | 2020-11-06 | 서울대학교산학협력단 | 혈액 클렌징 시스템 |
WO2020036501A1 (en) * | 2018-08-17 | 2020-02-20 | Smela Krysztof | Multicompartment system of nanocapsule-in-nanocapsule type, for encapsulation of a lipophilic and hydrophilic compound, and the related production method |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5296228A (en) * | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
JP2002517085A (ja) | 1998-05-26 | 2002-06-11 | バー−イラン ユニバーシティ | 磁性金属酸化物ナノ粒子の核生成および成長ならびにその使用 |
JP2000203810A (ja) | 1999-01-14 | 2000-07-25 | Toyota Central Res & Dev Lab Inc | 中空状酸化物粉末粒子 |
ATE377652T1 (de) * | 1999-02-12 | 2007-11-15 | Stemcells Inc | Angereicherte zentralnervensystem- zellpopulationen |
DE60128123T2 (de) | 2000-10-27 | 2008-01-03 | Genencor International, Inc., Palo Alto | Teilchen beschichtet mit substituiertem polyvinylalkohol |
WO2004083902A2 (en) | 2002-10-25 | 2004-09-30 | Georgia Tech Research Corporation | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
JP4684991B2 (ja) * | 2003-01-31 | 2011-05-18 | ボストン サイエンティフィック リミテッド | 薬物添加ナノカプセルを用いる局所的薬物デリバリー |
US20050058603A1 (en) | 2003-05-02 | 2005-03-17 | Case Western Reserve University | Drug delivery system based on polymer nanoshells |
CN1302163C (zh) | 2003-08-22 | 2007-02-28 | 株式会社晓星 | 高强聚-2,6-萘二甲酸乙二酯纤维 |
CN1279554C (zh) | 2003-12-23 | 2006-10-11 | 中国科学院理化技术研究所 | 具有介孔结构的磁性氧化铁中空微球颗粒及其制法和用途 |
WO2006037229A1 (en) | 2004-10-06 | 2006-04-13 | Bc Cancer Agency | Formulation of multivalent antibody constructs and use of same for cancer therapy |
US20100267594A1 (en) | 2005-06-24 | 2010-10-21 | Rana Rohit K | Nano-encapsulated triggered-release viscosity breakers |
PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
US20070258889A1 (en) | 2005-11-09 | 2007-11-08 | Montana State University | Novel nanoparticles and use thereof |
KR100819378B1 (ko) | 2006-02-24 | 2008-04-04 | (주)에이티젠 | 양친매성 화합물을 이용한 자성 나노복합체 및 이를포함하는 약제학적 조성물 |
US9220709B2 (en) | 2006-05-19 | 2015-12-29 | Drexel University | Drug loaded contrast agents: combining diagnosis and therapy |
WO2008115854A2 (en) * | 2007-03-19 | 2008-09-25 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Multifunctional nanoparticles and compositions and methods of use thereof |
FR2918755B1 (fr) * | 2007-07-09 | 2009-10-30 | Commissariat Energie Atomique | Procede de detection et de quantification d'analytes sur support solide avec des molecules fluorescentes encapsulees dans des immunoliposomes. |
EP2039352A1 (en) | 2007-09-18 | 2009-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules |
CN201207042Y (zh) | 2008-04-21 | 2009-03-11 | 上海骏维实业有限公司 | 一种新型复合式pH电极 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CN101318710B (zh) | 2008-06-30 | 2011-12-14 | 中国科学院上海硅酸盐研究所 | 一种铁氧化物多级空心核壳材料及其制备方法 |
US20110305768A1 (en) * | 2008-07-01 | 2011-12-15 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
CN101475222B (zh) | 2009-01-22 | 2011-10-05 | 中国科学院上海硅酸盐研究所 | 铁氧化物空心微球及其制备方法 |
CN101536982B (zh) | 2009-04-27 | 2011-11-09 | 中国人民解放军第二军医大学 | Trastuzumab修饰的包裹毒素蛋白的PEG化免疫脂质体及其制备与应用 |
US20120108563A1 (en) | 2009-05-19 | 2012-05-03 | Infinity Pharmaceuticals, Inc. | Methods Of Treating Liposarcoma |
EP2432460B1 (en) | 2009-05-21 | 2015-04-22 | Institute Of Life Sciences | Water dispersible glyceryl monooleate magnetic nanoparticle formulation |
WO2011001276A1 (en) | 2009-06-30 | 2011-01-06 | Philogen S.P.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
TW201129380A (en) | 2009-12-04 | 2011-09-01 | Genentech Inc | Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1 |
US9308582B2 (en) * | 2009-12-24 | 2016-04-12 | Yi Sun | Solution stable and chemically reactive metallic nanoparticles |
CN102128864A (zh) | 2010-01-12 | 2011-07-20 | 上海葛宝水处理设备有限公司 | 微型复合电极 |
CA2818669A1 (en) | 2010-12-09 | 2012-06-14 | Barbara Klencke | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
TWI462753B (zh) * | 2011-11-29 | 2014-12-01 | Univ Nat Chiao Tung | 雙乳化核殼奈米結構及其製備方法 |
CN102580106B (zh) | 2012-03-21 | 2013-07-10 | 浙江大学 | 一种pH敏感型聚电解质微囊给药载体的制备方法 |
CN102746474B (zh) | 2012-08-27 | 2014-07-16 | 同济大学 | 一种温度和pH敏感性的壳交联聚合物胶束的制备方法 |
-
2013
- 2013-11-05 TW TW102140127A patent/TWI482782B/zh not_active IP Right Cessation
-
2014
- 2014-04-24 US US14/260,726 patent/US9603798B2/en not_active Expired - Fee Related
- 2014-05-30 CN CN201410238809.8A patent/CN104208717B/zh not_active Expired - Fee Related
- 2014-05-30 WO PCT/US2014/040107 patent/WO2014194150A1/en active Application Filing
- 2014-05-30 RU RU2015148841A patent/RU2015148841A/ru not_active Application Discontinuation
- 2014-05-30 AU AU2014274028A patent/AU2014274028B2/en not_active Ceased
- 2014-05-30 BR BR112015028869A patent/BR112015028869A2/pt not_active IP Right Cessation
- 2014-05-30 CA CA2910076A patent/CA2910076C/en not_active Expired - Fee Related
- 2014-05-30 JP JP2016514169A patent/JP6335281B2/ja not_active Expired - Fee Related
- 2014-05-30 KR KR1020157033594A patent/KR101767906B1/ko active IP Right Grant
- 2014-05-30 EP EP14804482.9A patent/EP3003280A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
TWI482782B (zh) | 2015-05-01 |
US9603798B2 (en) | 2017-03-28 |
RU2015148841A (ru) | 2017-07-05 |
WO2014194150A1 (en) | 2014-12-04 |
CN104208717B (zh) | 2017-08-25 |
CA2910076C (en) | 2017-08-15 |
KR101767906B1 (ko) | 2017-08-14 |
US20140356421A1 (en) | 2014-12-04 |
TW201444874A (zh) | 2014-12-01 |
AU2014274028B2 (en) | 2017-05-25 |
AU2014274028A1 (en) | 2015-11-12 |
CA2910076A1 (en) | 2014-12-04 |
KR20160042814A (ko) | 2016-04-20 |
CN104208717A (zh) | 2014-12-17 |
JP2016518454A (ja) | 2016-06-23 |
EP3003280A4 (en) | 2017-01-11 |
JP6335281B2 (ja) | 2018-05-30 |
EP3003280A1 (en) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015028869A2 (pt) | nanocápsula de emulsão dupla conjugada de anticorpo e métodos de preparação da mesma | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
CL2016002262A1 (es) | Composiciones y métodos para modular la expresión de ttr y vhb | |
BR112016024508A2 (pt) | emulsão, processo para preparação de uma emulsão, e, uso de uma emulsão | |
BR112016010422A8 (pt) | suplemento dietético, e uso de uma composição | |
CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
CL2016000839A1 (es) | Composiciones para modular la expresión de c9orf72. | |
BR112018075250A2 (pt) | composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0 | |
CL2016001723A1 (es) | Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos. | |
CL2017001924A1 (es) | Anticuerpos anti-transtiretina | |
CL2018003489A1 (es) | Composición y método para reducir neutropenia | |
BR112017005522A2 (pt) | abas de aplicação heterogênea | |
BR112017011234A2 (pt) | anticorpos contra receptor da barreira hematoencefálica e métodos de uso | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
CU20170098A7 (es) | Anticuerpos anti-transtiretina | |
CL2018002645A1 (es) | Sulfonamidas sustituidas para controlar plagas animales | |
ES2969960T3 (es) | Método para conjugar un polipéptido | |
BR112015024332A2 (pt) | sonda fluorescente para estanho | |
BR112017010613A2 (pt) | carenagem de aleta dupla | |
BR112015007943A2 (pt) | fogão do tipo "cooktop" por indução | |
BR112015019424A2 (pt) | papel de base para materiais de revestimento decorativos | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
BR112017003790A2 (pt) | disposição de sensor de curso de pistão para uma unidade de frenagem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |